Arcellx Inc (ACLX)
55.18
+1.06
(+1.96%)
USD |
NASDAQ |
Jun 28, 16:00
55.21
+0.03
(+0.05%)
After-Hours: 20:00
Arcellx Research and Development Expense (Annual): 133.85M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 133.85M |
| December 31, 2022 | 149.56M |
| December 31, 2021 | 46.88M |
| Date | Value |
|---|---|
| December 31, 2020 | 25.06M |
| December 31, 2019 | 15.77M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
15.77M
Minimum
2019
149.56M
Maximum
2022
74.22M
Average
46.88M
Median
2021
Research and Development Expense (Annual) Benchmarks
| BridgeBio Pharma Inc | 455.71M |
| Gilead Sciences Inc | 5.718B |
| Agios Pharmaceuticals Inc | 295.53M |
| Krystal Biotech Inc | 46.43M |
| Arvinas Inc | 379.70M |